Over 52 weeks, resolution of MASH without worsening of fibrosis was achieved in 10% of the placebo group, 44% of the tirzepatide 5 mg group, 56% of the 10 mg group, and 62% of the 15 mg group
Published COAs Every Certificate of Analysis is uploaded publicly and linked from the matching product page
Conclusion This exit interview study provides qualitative evidence to support the interpretation of the clinical trial findings for retatrutide in the treatment of obesity, with detailed descriptions from participants of positive experiences relating to weight loss, eating behaviors, physical aspects, emotions, and lifestyle
If a licensed Nexa provider determines you're not eligible for GLP-1 therapy, you receive a full refund before anything ships
Analysis of nearly 8,000 adults found 45% keep the weight off after one year As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings
Significant pain and medical bills